– 755 . 5 Burris HA 3rd Moore MJ Andersen J . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413
Search Results
Treatment of Metastatic Pancreatic Cancer
Andrew H. Ko and Margaret A. Tempero
Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience
Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan
experienced recurrence at an average interval of 9.6 (± 8.7) months. Most patients who received chemotherapy were ultimately treated with a gemcitabine-based regimen (57/68); 16 (23.5%) received gemcitabine alone or in combination with a fluoropyrimidine (5
Multidisciplinary Management of Pancreatic Cancer
Margaret A. Tempero
essentially be summarized as a half dozen clinical trials evaluating gemcitabine and 5-fluorouracil (FU), with and without radiation. Outcomes from these trials were largely similar, with median OS hovering around 22 months and 25% to 30% of patients dying of
Pancreatic Adenocarcinoma
Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff
performed after administration of each treatment modality, when systemic gemcitabine is followed by chemoradiation in the adjuvant setting. In addition, this restaging is also recommended after administration of neoadjuvant therapy and before surgical
PCL20-117: Can Green Tea Extract Inhibit the Tumor Growth and Invasiveness of 5-FU and Gemcitabine-Resistant Metastatic and Remetastatic Cell Lines in a Hamster Pancreatic Cancer Model?
Cintia Yoko Morioka, Marcel Cerqueira Cesar Machado, Jose Pinhata Otoch, Luma Princess Schneider, Edgard Mesquita Rodrigues Lima, Marcelo Engracia Garcia, Joelmir Silva, Alessandro Costa, Victor Herrera, Paulo Aguiar, Elenir Herrera, Talita Aguiar, Maycon Kublik, Amelia Silva, Kennedy Silva, Eduardo Morioka, and Ching Cheng Huang
were used for the experiments. 5-Fluorouracil (5FU), Gemcitabine (GEM) and green tea extract (GTE) were used. MTT assay and MTT agarose assay were performed. In vitro chemoinvasion assay was done. RESULTS: The inhibitory concentration (IC50) of 5-FU
Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?
Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara
Lord RV Brabender J Gandara D . Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer . Clin Cancer Res 2002 ; 8 : 2286 – 2291 . 11 Rosell-Costa R Danenberg K
Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach
Heike Reinhardt, Rainer Trittler, Alison G. Eggleton, Stefan Wöhrl, Thomas Epting, Marion Buck, Sabine Kaiser, Daniel Jonas, Justus Duyster, Manfred Jung, Martin J. Hug, and Monika Engelhardt
. 8 The number of production cycles required per year was determined from published stability data by dividing 52 by the stability in weeks of the respective drug. 10 , 11 Using gemcitabine as an example, assuming a stability of 12 weeks, 11 5
Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma
Keli Turner, Sheelu Varghese, and H. Richard Alexander
overall response rates (including no complete responders in both groups), suggesting either regimen may be used beyond first-line chemotherapy. Table 1 Pemetrexed Alone Versus With Cisplatin or Gemcitabine The results of a second phase II
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
, chemotherapy is the cornerstone of treatment. 3 – 5 However, international consensus on the most optimal first- and second-line palliative systemic treatment regimen is lacking. Since 1997, single-agent gemcitabine has been the standard first-line palliative
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™
-37. Factors Potentially Associated With Gemcitabine-Based, Chemotherapy-Induced Thrombocytopenia in Chinese Patients With Non–Small Cell Lung Cancer Zeng Wang; Ling Ya Chen; Wen Xiu Xin; Bin Cheng; and Ping Huang From Zhejiang Cancer Hospital, People
